AIM: Adolescents with psychotic disorders show deficits in IQ, attention, learning and memory, executive functioning, and processing speed that are related to important clinical variables including negative symptoms, adaptive functioning and academics. Previous studies have reported relatively consistent deficits with varying relationships to illness status and symptoms. The goals of this study were to examine these relationships in a larger sample at baseline, and also to examine the longitudinal course of these deficits in a smaller subset of adolescents. METHOD: Thirty-six subjects, aged 10 to 17 years, were included at baseline. All had Diagnostic and Statistical Manual-Fourth Edition diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder and psychosis - not otherwise specified, as determined by Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children structured interviews. Patients were administered a neuropsychological battery, and Positive and Negative Syndrome Scale ratings were completed at baseline and again at 1 year (n = 14). Most participants were inpatients at baseline, and 13 of 14 were on atypical antipsychotic medication during both sessions. RESULTS: At baseline, the patients demonstrated impairments in working memory, processing speed, executive function and verbal learning. No significant cognitive change was detected at 1-year follow-up. In contrast, clinical symptoms were variable across 1 year, with an improvement in positive symptoms at 1 year. No relationships between clinical and cognitive symptoms were observed, with the exception of baseline IQ predicting negative symptoms at 1 year. CONCLUSIONS: Young patients with schizophrenia-spectrum disorders displayed neurocognitive impairments at baseline. Despite measurable fluctuations in clinical symptoms over the year, no significant changes were measured in cognition. Lower IQ at baseline was predictive of more negative symptoms at 1 year.
AIM: Adolescents with psychotic disorders show deficits in IQ, attention, learning and memory, executive functioning, and processing speed that are related to important clinical variables including negative symptoms, adaptive functioning and academics. Previous studies have reported relatively consistent deficits with varying relationships to illness status and symptoms. The goals of this study were to examine these relationships in a larger sample at baseline, and also to examine the longitudinal course of these deficits in a smaller subset of adolescents. METHOD: Thirty-six subjects, aged 10 to 17 years, were included at baseline. All had Diagnostic and Statistical Manual-Fourth Edition diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder and psychosis - not otherwise specified, as determined by Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children structured interviews. Patients were administered a neuropsychological battery, and Positive and Negative Syndrome Scale ratings were completed at baseline and again at 1 year (n = 14). Most participants were inpatients at baseline, and 13 of 14 were on atypical antipsychotic medication during both sessions. RESULTS: At baseline, the patients demonstrated impairments in working memory, processing speed, executive function and verbal learning. No significant cognitive change was detected at 1-year follow-up. In contrast, clinical symptoms were variable across 1 year, with an improvement in positive symptoms at 1 year. No relationships between clinical and cognitive symptoms were observed, with the exception of baseline IQ predicting negative symptoms at 1 year. CONCLUSIONS: Young patients with schizophrenia-spectrum disorders displayed neurocognitive impairments at baseline. Despite measurable fluctuations in clinical symptoms over the year, no significant changes were measured in cognition. Lower IQ at baseline was predictive of more negative symptoms at 1 year.
Authors: Wiepke Cahn; Hilleke E Hulshoff Pol; Elleke B T E Lems; Neeltje E M van Haren; Hugo G Schnack; Jeroen A van der Linden; Patricia F Schothorst; Herman van Engeland; René S Kahn Journal: Arch Gen Psychiatry Date: 2002-11
Authors: S Kumra; E Wiggs; J Bedwell; A K Smith; E Arling; K Albus; S D Hamburger; K McKenna; L K Jacobsen; J L Rapoport; R F Asarnow Journal: Schizophr Res Date: 2000-04-07 Impact factor: 4.939
Authors: H E Hulshoff Pol; H G Schnack; R C Mandl; N E van Haren; H Koning; D L Collins; A C Evans; R S Kahn Journal: Arch Gen Psychiatry Date: 2001-12
Authors: Thomas J Whitford; Stuart M Grieve; Tom F D Farrow; Lavier Gomes; John Brennan; Anthony W F Harris; Evian Gordon; Leanne M Williams Journal: Neuroimage Date: 2006-05-03 Impact factor: 6.556
Authors: Eugenia Kravariti; Robin G Morris; Sophia Rabe-Hesketh; Robin M Murray; Sophia Frangou Journal: Schizophr Res Date: 2003-12-15 Impact factor: 4.939
Authors: A L Hoff; D Harris; W O Faustman; M Beal; D DeVilliers; R D Mone; J A Moses; J G Csernansky Journal: Schizophr Res Date: 1996-05 Impact factor: 4.939
Authors: Ditte L Vernal; Sandeep Kapoor; Aseel Al-Jadiri; Eva M Sheridan; Yehonathan Borenstein; Charles Mormando; Lisa David; Sukhbir Singh; Andrew J Seidman; Maren Carbon; Miriam Gerstenberg; Ema Saito; John M Kane; Hans-Christoph Steinhausen; Christoph U Correll Journal: J Child Adolesc Psychopharmacol Date: 2015-09 Impact factor: 2.576
Authors: Ana Catalan; Claudia J P Simons; Sonia Bustamante; Nora Olazabal; Eduardo Ruiz; Maider Gonzalez de Artaza; Alberto Penas; Claudio Maruottolo; Claudio Maurottolo; Andrea González; Jim van Os; Miguel Angel Gonzalez-Torres Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240
Authors: Covadonga M Díaz-Caneja; Laura Pina-Camacho; Alberto Rodríguez-Quiroga; David Fraguas; Mara Parellada; Celso Arango Journal: NPJ Schizophr Date: 2015-03-04
Authors: Ana Catalan; Maider Gonzalez de Artaza; Sonia Bustamante; Pablo Orgaz; Luis Osa; Virxinia Angosto; Cristina Valverde; Amaia Bilbao; Arantza Madrazo; Jim van Os; Miguel Angel Gonzalez-Torres Journal: PLoS One Date: 2016-07-28 Impact factor: 3.240